AG
EVLO

Artal Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Artal Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$6.07M – 153
2021
Q4 		$6.07M Hold
50,000
– – 0.16% 94
2021
Q3 		$7.04M Hold
50,000
– – 0.16% 99
2021
Q2 		$13.7M Hold
50,000
– – 0.28% 75
2021
Q1 		$10.7M Buy
50,000
+15,000
+43% +$4.15M 0.19% 97
2020
Q4 		$8.46M Buy
35,000
+11,250
+47% +$1.39M 0.18% 91
2020
Q3 		$2.5M Sell
23,750
-9,583
-29% -$873K 0.06% 118
2020
Q2 		$3.27M Buy
+33,333
New +$2.92M 0.09% 117

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artal Group's EVLO Position: Q1 2022 in Review

Artal Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2022, closing a stake of 50,000 shares — an estimated $6.07M sold.

Artal Group first reported a position in EVLO in Q2 2020 and held it in 7 quarters. The position peaked at $13.7M in Q2 2021. 68 funds tracked by Wall St. Rank hold EVLO as of Q1 2022.

  • Artal Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Artal Group sold 50,000 Evelo Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $6.07M.
  • Artal Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • Artal Group's Evelo Biosciences, Inc. Common Stock position peaked at $13.7M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2022.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.